Effect of anlotinib hydrochloride combined with gemcitabine plus cisplatin on T lymphocyte subsets and tumor marker levels in patients with advanced NSCLC
Objective:To observe the effect of anlotinib hydrochloride combined with gemcitabine plus cisplatin(GP)chemotherapy on T lymphocyte subsets and tumor marker levels in patients with advanced non-small cell lung cancer(NSCLC).Methods:Sixty patients with advanced NSCLC treated in the hospital from October 2021 to October 2023 were selected,and randomly grouped.The control group(n=30)was treated with GP regimen,while the study group(n=30)was treated with anlotinib hydrochloride combined with GP regimen.Therapeutic effects,T lymphocyte subsets,and tumor marker levels in the two groups were observed and compared.Results:Compared with control group,the disease control rate was significantly higher in study group(P<0.05).After treatment,CD3+levels in both groups increased significantly.There were significant increases in CD4+and CD4+/CD8+levels,and a significant decrease in CD8+level in study group.However,there was no significant change in the control group.The differences between groups were significant(P<0.05).After treatment,the levels of CEA and CYFRA21-1 in both groups decreased significantly,with the levels were lower in study group(P<0.05).Conclusion:Anlotinib hydrochloride combined with GP regimen is more effective in the treatment of patients with advanced NSCLC.It can regulate the levels of T lymphocyte subsets and tumor markers in patients more significantly.
NETL
NSTL
万方数据
